Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oklahoma for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oklahoma only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oklahoma (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

William Surbeck (NPI 1154382711)

Field	Value
Entity Type	Individual
Organization	William Surbeck
Address	4812 S 109th East Ave
City	Tulsa
State	OK
ZIP	74146
Taxonomy	Rheumatology Physician
NPI Enumerated	March 31, 2006

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

This provider's public-payer activity is effectively single‑payer: lifetime Medicare revenue is $1.8M while Medicaid is reported as none (no Medicaid billing on file). In practical terms payer mix and public-revenue exposure in the datasets are concentrated entirely in Medicare, so analyses of public reimbursement should be framed around Medicare-only patterns.

Revenue concentration is high among a few biologic infusion drugs: the precomputed top 3 Medicare codes by revenue account for 62.8% of this provider's total Medicare revenue. Those three codes are J0129 ($417.4K, 23.3%), J0717 ($372.8K, 20.8%), and J9312 ($333.1K, 18.6%), indicating a concentrated revenue base in a small number of high-cost injectable agents.

The code mix points to an infusion- and in-office biologic administration practice consistent with rheumatology specialty care: J0129 (abatacept), J0717 (certolizumab pegol), and J9312 (rituximab) are the top revenue drivers, and additional high-revenue procedure codes such as J1602 ($297.6K, 16.6%) and infusion/chemotherapy administration codes 96413 (287 claims, $24.4K) and 96365 (335 claims, $14.4K) support the presence of IV administration capacity. This pattern suggests the practice is organized to deliver and bill for supervised injectable biologic therapies rather than relying on predominantly office E/M-only revenue.

Competitive standing is mixed across the provider's top biologics: J9312 ranks #57 of 317 (82th percentile; typical, unremarkable volume for this code) indicating relatively high rituximab use versus peers, while J0717 ranks #167 of 848 (80th percentile; typical, unremarkable volume for this code) and J0129 ranks #357 of 1221 (71th percentile; typical, unremarkable volume for this code). In other words, the provider is not a national dominant outlier across all biologics but shows above-average activity on specific agents, notably rituximab.

Service-volume signals show important operational scale in office visits and injections: 99214 appears as an extreme statistical outlier (1.2K claims, $96.7K revenue, 5.4% of Medicare; ranks #7252 of 479517, 98th percentile; extreme outlier, far above typical national volume), and 96372 is notably above typical (556 claims, $5.6K revenue, 0.3% of Medicare; ranks #1336 of 58224, 98th percentile; notably above typical national volume). These findings indicate higher-than-typical established‑patient E/M throughput and frequent in‑office injections relative to national peers, consistent with a busy ambulatory infusion/injection practice.

The provider has an established billing history with long tenure in the Medicare dataset: NPI enumerated on 2006-03-31 (~20 years ago). This longevity supports the interpretation that the observed biologic- and infusion-focused mix represents a sustained practice pattern rather than a short-term fluctuation.

From a business and payer-negotiation perspective, the combination of concentrated biologic drug revenue (top 3 = 62.8% of Medicare revenue) and the absence of Medicaid billing (none (no Medicaid billing on file)) creates both opportunity and exposure: the provider likely has operational expertise and infrastructure for administering high-cost injectables which can be leveraged in contracting, but the public-revenue profile is dependent on Medicare reimbursement dynamics for a few agents. Payers assessing network value should weigh the provider's specialized infusion capability against the concentration risk in a small set of biologic codes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	12,280	$30	$417.4K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	93,200	$1	$372.8K
J9312	Injection, rituximab, 10 mg	5,460	$60	$333.1K
J1602	Injection, golimumab, 1 mg, for intravenous use	27,050	$10	$297.6K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,430	$30	$141.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,190	$80	$96.7K
J0897	Injection, denosumab, 1 mg	3,840	$20	$69.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	290	$90	$24.4K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	340	$40	$14.4K
96372	A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician…	560	$10	$5.6K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oklahoma Distribution

William Surbeck — 2 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oklahoma

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	10	10	16,680	$30	$661.9K
J1602	7	20	25,400	$10	$412.3K
J1745	8	10	6,400	$30	$312.2K
J0717	2	10	60,800	$1	$255.6K
J9312	2	10	3,650	$60	$246.8K
J0897	21	70	2,130	$20	$91.2K
96413	23	60	210	$90	$26.4K
99214	115	5,560	130	$70	$18.4K
99213	3,604	5,450	80	$50	$8.7K
96365	11	80	60	$40	$6.9K

Showing 1–10 of 19

Related Providers

Other providers that share a Tax Identification Number (TIN) with William Surbeck, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tulsa Bone & Joint Associates PC	OK	Orthopaedic Surgery Physician	$0	$3M
Alan Martin	OK	Rheumatology Physician	$1.5M	$0
Mindy Ewert	OK	Physician Assistant	$1.1M	$0
Lindsay Cunningham	OK	Rheumatology Physician	$502.1K	$0
James Slater	OK	Adult Reconstructive Orthopaedic Surgery Physician	$352.3K	$0
Justin Reid	OK	Adult Reconstructive Orthopaedic Surgery Physician	$335.5K	$0
Christopher Martin	OK	Pain Medicine (Physical Medicine & Rehabilitation) Physician	$311.7K	$0
Hayley Sewell	OK	Physician Assistant	$310.7K	$0
Caleb Nunley	OK	Sports Medicine (Family Medicine) Physician	$303.3K	$0
Brian Lovelace	OK	Orthopaedic Surgery Physician	$302.2K	$0

Nearby Providers

Other providers in the same ZIP code as William Surbeck, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Option 1 Nutrition Solutions LLC	OK	Durable Medical Equipment & Medical Supplies	$0	$18.8M
Regional Medical Laboratory, Inc	OK	Clinical Medical Laboratory	$0	$17.6M
Labcorp Oklahoma, Inc.	OK	Clinical Medical Laboratory	$6.8M	$7.8M
Access Pain Solutions	OK	Pain Medicine Physician	$0	$13.1M
Osu Center For Health Sciences	OK	Medical Specialty Clinic/Center	$0	$10.5M
Advanced Pediatric Care	OK	Durable Medical Equipment & Medical Supplies	$0	$4.9M
Asm LLC	OK	Customized Equipment (DME)	$0	$4.7M
Pathology Laboratory Associates, Inc.	OK	Anatomic Pathology & Clinical Pathology Physician	$22.2K	$3.9M
Sleep Management, L.L.C.	OK	Oxygen Equipment & Supplies (DME)	$0	$3.6M
Ocean Dental, P.C.	OK	General Practice Dentistry	$0	$3M

William Surbeck — Billing Profile & Reimbursement Data

Sign up for William Surbeck — Billing Profile & Reimbursement Data policy alerts

William Surbeck — Billing Profile & Reimbursement Data

Sign up for William Surbeck — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References